ArticleCNS neuroscience & therapeutics2014
Prognostic value of a nine-gene signature in glioma patients based on mRNA expression profiling.
Article in CNS neuroscience & therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled analysis of prognostic value and clinical significance of Rab1A expression in human solid tumors.Medicine · 2019Pooled it
- Artificial Intelligence-Driven Multi-Omics Approaches in Glioblastoma.International journal of molecular sciences · 2025Review
- The immune-related prognostic gene AIM2 promotes pancreatic cancer progression via inflammasome.Scientific reports · 2025Article
- Integrative machine learning model for subtype identification and prognostic prediction in lung squamous cell carcinoma.Discover oncology · 2025Article
- Integrated multi-optosis model for pan-cancer candidate biomarker and therapy target discovery.Frontiers in bioinformatics · 2025Article
- Signature Genes Selection and Functional Analysis of Astrocytoma Phenotypes: A Comparative Study.Cancers · 2024Article
- Gene features of tumor-specific T cells relevant to immunotherapy, targeted therapy and chemotherapy in lung cancer.Heliyon · 2024Article
- Tubulin alpha-1b chain was identified as a prognosis and immune biomarker in pan-cancer combing with experimental validation in breast cancer.Scientific reports · 2024Article
- Two decades of progress in glioma methylation research: the rise of temozolomide resistance and immunotherapy insights.Frontiers in neuroscience · 2024Article
- Bioinformatics Analysis and Screening of Potential Target Genes Related to the Lung Cancer Prognosis.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2023Article
- Deep learning algorithm reveals two prognostic subtypes in patients with gliomas.BMC bioinformatics · 2022Article
- Identification of an immune-related gene signature as a prognostic target and the immune microenvironment for adrenocortical carcinoma.Immunity, inflammation and disease · 2022Article
- An immune-associated ten-long noncoding RNA signature for predicting overall survival in cervical cancer.Translational cancer research · 2021Article
- A novel survival model based on a Ferroptosis-related gene signature for predicting overall survival in bladder cancer.BMC cancer · 2021Article
- Prognostic value of eight immune gene signatures in pancreatic cancer patients.BMC medical genomics · 2021Article
- Identification of NNeurosurgical review · 2021Article
- Transcriptome analysis and prognostic model construction based on splicing profiling in glioblastoma.Oncology letters · 2021Article
- Transcriptome-wide Mendelian randomization study prioritising novel tissue-dependent genes for glioma susceptibility.Scientific reports · 2021Article
- An mRNA characterization model predicting survival in patients with invasive breast cancer based on The Cancer Genome Atlas database.Cancer biomarkers : section A of Disease markers · 2021Article
- Identification of a Novel Epithelial-Mesenchymal Transition Gene Signature Predicting Survival in Patients With HNSCC.Pathology oncology research : POR · 2021Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGliomas are the most common primary brain tumors in adults and a significant cause of cancer-related mortality. A 9-gene signature was identified as a novel prognostic model reflecting survival situation obviously in gliomas.
aimsTo identify an mRNA expression signature to improve outcome prediction for patients with different glioma grades.
resultsWe used whole-genome mRNA expression microarray data of 220 glioma samples of all grades from the Chinese Glioma Genome Atlas (CGGA) database (http://www.cgga.org.cn) as a discovery set and data from Rembrandt and GSE16011 for validation sets. Data from every single grade were analyzed by the Kaplan-Meier method with a two-sided log-rank test. Univariate Cox regression and linear risk score formula were applied to derive a gene signature with better prognostic performance. We found that patients who had high risk score according to the signature had poor overall survival compared with patients who had low risk score. Highly expressed genes in the high-risk group were analyzed by gene ontology (GO) and gene set variation analysis (GSVA). As a result, the reason for the divisibility of gliomas was likely due to cell life processes and adhesion.
conclusionThis 9-gene-signature prediction model provided a more accurate predictor of prognosis that denoted patients with high risk score have poor outcome. Moreover, these risk models based on defined molecular profiles showed the considerable prospect in personalized cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.